Global Candida Infections Drugs Market – Industry Trends and Forecast to 2029

Candida Infections Drugs Market Analysis and Size

The global candida infections drugs market is expected to witness significant growth during the forecast period. The growing prevalence rate of fungal infections such as candidiasis and aspergillosis is one of the key factors propelling the market. With respect to its treatment, the increasing popularity of over-the-counter (OTC) drugs such as econazole, ketoconazole, miconazole,clotrimazole, and amorolfine, many patients are found to be taking OTC drugs to obtain a prescription from a health professional.

Data Bridge Market Research analyses a growth rate in the global candida infections drugs market in the forecast period 2022-2029. The expected CAGR of the global candida infections drugs market tends to be around 4.00% in the mentioned forecast period. The market was valued at USD 14.42 billion in 2021, and it would grow up to USD 19.73 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Candida Infections Drugs Market Scope and Segmentation

Market Definition

Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.

Global Candida Infections Drugs Market Dynamics

Drivers

• Higher Demand for Azoles

Synthetic azoles and semi-synthetic compounds are widely used for more fungal infections and infections. These drugs are used to treat thrush, candidiasis, aspergillosis, yeast infection, tinea versicolor, athlete's foot, ringworm, fungal infections, systemic mycosis, and seborrheic dermatitis. The azole group provides a broad spectrum of activity and improved safety standards. These medications have fewer side effects, worse drug interactions, and improved absorption and distribution properties. Thus, it acts as a major driver in market growth.

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by the rise in the number of research and development activities. This will provide beneficial opportunities for the global candida infection drugs market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government funds research and development (R&D) initiatives.

Opportunities

• Higher Drug Launches and Innovations

The development and innovation of many potential drugs support the competitiveness of the pharmaceutical market. The sale of both established agents and newly launched antifungal agents is important. For instance, in 2019, Mayne Pharma announced the launch of the TOLSURA 65mg capsule in the U.S. TOLSURA is a formulation of itraconazole that has been shown to treat fungal infections of the system, including histoplasmosis, blastomycosis, aspergillosis, and others. Therefore, all of these factors are projected to contribute to partial growth in the forecast period.  

• Increasing Demand for Retail Pharmacies

The increase in the number of drugs used for global candida infections delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could reduce the growth of the global candida infections drugs market over a forecast period.

• Unavailability of Appropriate Treatments

To treat conditions that are rare, many a time, all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.

This global candida infections drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global candida infections drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Candida Infections Drugs Market Scope

The global candida infections drugs market is segmented on the basis of type, drug type, treatment, dosage form, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Athletes Foot
• Oral Thrush
• Vaginal Yeast Infection
• Nail Fungus
• Jock Itch
• Diaper Rash 

Drug Type

• Azoles
• Echinocandins
• Other Drugs

Treatment

• Antibiotics
• Benzodiazepines
• Contraceptives
• Hormone Replacement Therapy

Dosage Form

• Gels and Creams
• Lozenges
• Tablets
• Liquids
• Sprays
• Powders
• Ointments

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Candida Infections Drugs Market Regional Analysis/Insights

The global candida infections drugs market is analysed and market size insights and trends are provided by type, drug type, treatment, dosage form,end-user, distribution channel as referenced above.

The major countries covered in the global candida infections drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the highest investment in healthcare and awareness.

Asia-Pacific is considered to have the most lucrative period due to the developing healthcare facilities, large number of generic manufacturers, and rise in government initiatives

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Candida Infections Drugs Market Share Analysis

The global candida infections drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global candida infections drugs market.

Key players operating in the global candida infections drugs market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)

SKU-55728